Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Marcoux

MS18.03 Treatment of SCLC Transformed From EGFR Mutant Adenocarcinoma

Journal of Thoracic Oncology

English

MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement

Journal of Thoracic Oncology

English

Related publications

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

2014

English

Targeting Alveolar Macrophages Shows Better Treatment Response Than Deletion of Interstitial Macrophages in EGFR Mutant Lung Adenocarcinoma

Immunity, inflammation and disease

Allergy

Immunology

2020

English

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Journal of Thoracic Oncology

English

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?

Translational Lung Cancer Research

Oncology

2017

English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy

Oncology

Pharmacology

2015

English

LAPTM4B Is a Novel Diagnostic and Prognostic Marker for Lung Adenocarcinoma and Associated With Mutant EGFR

English

Growth Inhibition of KRAS‑�and EGFR‑mutant Lung Adenocarcinoma by Cosuppression of STAT3 and the SRC/ARHGAP35 Axis

English

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

English

P1-175Heterogeneity of EGFR-mutant and PD-L1 High-Expressing Clones Affects Treatment Efficacy of EGFR-TKI and PD-1 Inhibitor

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N. Marcoux

MS18.03 Treatment of SCLC Transformed From EGFR Mutant Adenocarcinoma

MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient With Acquired RET Rearrangement

Related publications

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Targeting Alveolar Macrophages Shows Better Treatment Response Than Deletion of Interstitial Macrophages in EGFR Mutant Lung Adenocarcinoma

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Can We Omit Radiotherapy in Case of Brain Metastases for Patients With Mutant EGFR Lung Adenocarcinoma?

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

LAPTM4B Is a Novel Diagnostic and Prognostic Marker for Lung Adenocarcinoma and Associated With Mutant EGFR

Growth Inhibition of KRAS‑�and EGFR‑mutant Lung Adenocarcinoma by Cosuppression of STAT3 and the SRC/ARHGAP35 Axis

Correction To: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined With Chemotherapy Delay Brain Metastasis in Patients With EGFR‑Mutant Lung Adenocarcinoma

P1-175Heterogeneity of EGFR-mutant and PD-L1 High-Expressing Clones Affects Treatment Efficacy of EGFR-TKI and PD-1 Inhibitor